骨肉瘤免疫微环境中肿瘤相关巨噬细胞及其靶向治疗的研究进展

doi:10.3969/j.issn.1674-8115.2023.05.014

上海交通大学学报（医学版） ›› 2023, Vol. 43 ›› Issue (5): 624-630.doi: 10.3969/j.issn.1674-8115.2023.05.014

• 综述 • 上一篇

骨肉瘤免疫微环境中肿瘤相关巨噬细胞及其靶向治疗的研究进展

魏兰懿¹(), 薛晓川¹, 陈君君¹, 杨全军¹, 王梦月², 韩永龙¹()

^1.上海交通大学医学院附属第六人民医院药剂科，上海 200030
^2.上海交通大学药学院，上海 201109

收稿日期:2023-02-03 接受日期:2023-03-30 出版日期:2023-05-28 发布日期:2023-07-11
通讯作者: 韩永龙 E-mail:26062x@sjtu.edu.cn;yonglongh@126.com
作者简介:魏兰懿（1998—），女，硕士生；电子信箱：26062x@sjtu.edu.cn。
基金资助:
国家自然科学基金(82003987);上海市儿童基金会公益项目

Research progress of tumor-associated macrophages in immune microenvironment and targeted therapy of osteosarcoma

WEI Lanyi¹(), XUE Xiaochuan¹, CHEN Junjun¹, YANG Quanjun¹, WANG Mengyue², HAN Yonglong¹()

^1.Department of Pharmacy, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
^2.School of Pharmacy, Shanghai Jiao Tong University, Shanghai 201109, China

Received:2023-02-03 Accepted:2023-03-30 Online:2023-05-28 Published:2023-07-11
Contact: HAN Yonglong E-mail:26062x@sjtu.edu.cn;yonglongh@126.com
Supported by:
National Natural Science Foundation of China(82003987);Public Welfare Project of Children′s Fund of Shanghai

摘要/Abstract

摘要：

骨肉瘤（osteosarcoma，OS）是儿童和青少年常见的原发性恶性骨肿瘤，其易复发性和高转移率已成为目前临床亟待解决的难题，尚无有效的治疗方法。近年来有研究提示靶向肿瘤微环境很有可能成为OS新的治疗方向。肿瘤微环境中免疫细胞浸润可促进肿瘤炎症发生和肿瘤血管生成。肿瘤相关巨噬细胞（tumor-associated macrophages，TAMs）是肿瘤微环境中最重要的免疫细胞，在OS发展及转移中发挥重要作用。该文综述了TAMs极化对肿瘤细胞的作用，并从TAMs影响OS肿瘤生长及侵袭转移，介导OS化学治疗耐药、干细胞样表型以及免疫抑制方面，分析TAMs对OS发生和发展过程的影响；总结近年通过靶向TAMs发挥对OS治疗作用的研究进展，包括影响TAMs募集、促使M2型TAMs向M1型极化、靶向CD47促进TAMs的吞噬作用和靶向TAMs免疫检查点，旨在为OS的靶向治疗提供新方向和新思路。

关键词: 骨肉瘤, 肿瘤相关巨噬细胞, 肿瘤微环境, 靶向治疗

Abstract:

Osteosarcoma (OS) is a common primary malignant bone tumor in children and adolescents. The high recurrence and metastasis rate have become a common clinical problem to be solved, but there is no effective treatment. In recent years, studies have suggested that targeting the tumor microenvironment will likely become a new treatment direction for OS. Immune cell infiltration in the tumor microenvironment can promote tumor inflammation and angiogenesis. Tumor-associated macrophages (TAMs) are the most important immune cells in the tumor microenvironment, which play important roles in the development and metastasis of OS. The article reviews the effect of TAMs polarization on tumor cells and describes the effect of TAMs on the occurrence and development of OS from five aspects, including TAMs affecting the growth, invasion and metastasis, mediating chemotherapy resistance, stem cell-like phenotype, and immunosuppression of OS. The review summarizes the research progress of targeting TAMs in the treatment of OS in the past years, including influencing the recruitment of TAMs, promoting the polarization of M2 type to M1 type, targeting CD47 to promote the phagocytosis of TAMs, and targeting the immune checkpoint of TAMs, aiming to provide new directions and ideas for targeted therapy of OS.

Key words: osteosarcoma, tumor-associated macrophages, tumor microenvironment, targeted therapy

中图分类号:

R392.5

魏兰懿, 薛晓川, 陈君君, 杨全军, 王梦月, 韩永龙. 骨肉瘤免疫微环境中肿瘤相关巨噬细胞及其靶向治疗的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(5): 624-630.

WEI Lanyi, XUE Xiaochuan, CHEN Junjun, YANG Quanjun, WANG Mengyue, HAN Yonglong. Research progress of tumor-associated macrophages in immune microenvironment and targeted therapy of osteosarcoma[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023, 43(5): 624-630.

参考文献 67

1	KELLEHER F C, O′SULLIVAN H. Monocytes, macrophages, and osteoclasts in osteosarcoma[J]. J Adolesc Young Adult Oncol, 2017, 6(3): 396-405.
2	HUANG Q, LIANG X, REN T, et al. The role of tumor-associated macrophages in osteosarcoma progression-therapeutic implications[J]. Cell Oncol (Dordr), 2021, 44(3): 525-539.
3	SPALATO M, ITALIANO A. The safety of current pharmacotherapeutic strategies for osteosarcoma[J]. Expert Opin Drug Saf, 2021, 20(4): 427-438.
4	CHONG Z X, YEAP S K, HO W Y. Unraveling the roles of miRNAs in regulating epithelial-to-mesenchymal transition (EMT) in osteosarcoma[J]. Pharmacol Res, 2021, 172: 105818.
5	RUFFELL B, COUSSENS L M. Macrophages and therapeutic resistance in cancer[J]. Cancer Cell, 2015, 27(4): 462-472.
6	ZHU T, HAN J, YANG L, et al. Immune microenvironment in osteosarcoma: components, therapeutic strategies and clinical applications[J]. Front Immunol, 2022, 13: 907550.
7	XUE R, ZHANG Q, CAO Q, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity[J]. Nature, 2022, 612(7938): 141-147.
8	折胜利, 宋兴华, 周杨, 等. 骨肉瘤细胞外泌体调控JAK2/STAT3信号通路影响成纤维细胞向肿瘤相关成纤维细胞转化 [J]. 西部医学, 2021, 33(8): 1096-1100, 1105.
	ZHE S L, SONG X H, ZHOU Y, et al. Effects of osteosarcoma cell exosomes on the transformation of fibroblasts into tumor-associated fibroblasts by regulating JAK2/STAT3 signaling pathway [J]. Western Medicine, 2021, 33(8): 1096-1100, 1105.
9	刘汉涛, 赵良虎, 秦宏敏. 骨髓间充质干细胞外泌体miR-25-3p调控骨肉瘤细胞增殖迁移及侵袭能力的功能与机制研究 [J]. 河北医学, 2022, 28(4): 529-534.
	LIU H T, ZHAO L H, QIN H M. Study on the function and mechanism of bone marrow mesenchymal stem cell exosomal miR-25-3p regulating the proliferation, migration and invasion of osteosarcoma cells [J]. Hebei Medicine, 2022, 28(4): 529-534.
10	WEI C, YANG C, WANG S, et al. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis[J]. Mol Cancer, 2019, 18(1): 64.
11	NOY R, POLLARD J W. Tumor-associated macrophages: from mechanisms to therapy[J]. Immunity, 2014, 41(1): 49-61.
12	MANTOVANI A, ALLAVENA P, MARCHESI F, et al. Macrophages as tools and targets in cancer therapy[J]. Nat Rev Drug Discov, 2022, 21(11): 799-820.
13	ANDERSON P M, MEYERS P, KLEINERMAN E, et al. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments[J]. Pediatr Blood Cancer, 2014, 61(2): 238-244.
14	HEYMANN M F, LÉZOT F, HEYMANN D. The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma[J]. Cell Immunol, 2019, 343: 103711.
15	XIE D, WANG Z, LI J, et al. Targeted delivery of chemotherapeutic agents for osteosarcoma treatment[J]. Front Oncol, 2022, 12: 843345.
16	刘莹莹, 文金生, 邢景军, 等. 原发性恶性骨肿瘤免疫疗法研究现状及展望 [J]. 生命的化学, 2022, 42(2): 283-290.
	LIU Y Y, WEN J S, XING J J, et al. Research status and prospect of immunotherapy for primary malignant bone tumors [J]. Chemistry of Life, 2022, 42(2): 283-290.
17	NIU J, YAN T, GUO W, et al. Identification of potential therapeutic targets and immune cell infiltration characteristics in osteosarcoma using bioinformatics strategy[J]. Front Oncol, 2020, 10: 1628.
18	QIU S Q, WAAIJER S J H, ZWAGER M C, et al. Tumor-associated macrophages in breast cancer: innocent bystander or important player?[J]. Cancer Treat Rev, 2018, 70: 178-189.
19	LIU Y, FENG W, DAI Y, et al. Single-cell transcriptomics reveals the complexity of the tumor microenvironment of treatment-naive osteosarcoma[J]. Front Oncol, 2021, 11: 709210.
20	REN S, ZHANG X, HU Y, et al. Blocking the Notch signal transduction pathway promotes tumor growth in osteosarcoma by affecting polarization of TAM to M2 phenotype[J]. Ann Transl Med, 2020, 8(17): 1057.
21	LI J, ZHAO C, LI Y, et al. Osteosarcoma exocytosis of soluble LGALS3BP mediates macrophages toward a tumoricidal phenotype[J]. Cancer Lett, 2022, 528: 1-15.
22	ZHANG H, LU J, LIU J, et al. Advances in the discovery of exosome inhibitors in cancer[J]. J Enzyme Inhib Med Chem, 2020, 35(1): 1322-1330.
23	HE F, DING G, JIANG W, et al. Effect of tumor-associated macrophages on lncRNA PURPL/miR-363/PDZD2 axis in osteosarcoma cells[J]. Cell Death Discov, 2021, 7(1): 307.
24	CUI J J, WANG Y, XUE H W. Long non-coding RNA GAS5 contributes to the progression of nonalcoholic fatty liver disease by targeting the microRNA-29a-3p/NOTCH2 axis[J]. Bioengineered, 2022, 13(4): 8370-8381.
25	YANG D, LIU K, FAN L, et al. LncRNA RP11-361F15.2 promotes osteosarcoma tumorigenesis by inhibiting M2-like polarization of tumor-associated macrophages of CPEB4[J]. Cancer Lett, 2020, 473: 33-49.
26	ZHANG H, YU Y, WANG J, et al. Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis[J]. Cancer Cell Int, 2021, 21(1): 192.
27	ZHONG L, LIAO D, LI J, et al. Rab22a-NeoF1 fusion protein promotes osteosarcoma lung metastasis through its secretion into exosomes[J]. Signal Transduct Target Ther, 2021, 6(1): 59.
28	HUO Y, LI Q, WANG X, et al. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2[J]. Oncotarget, 2017, 8(29): 46993-47006.
29	WANG W, SHEN H, CAO G, et al. Long non-coding RNA XIST predicts poor prognosis and promotes malignant phenotypes in osteosarcoma[J]. Oncol Lett, 2019, 17(1): 256-262.
30	WANG X, ZOU J, CHEN H, et al. Long noncoding RNA NORAD regulates cancer cell proliferation and migration in human osteosarcoma by endogenously competing with miR-199a-3p[J]. IUBMB Life, 2019, 71(10): 1482-1491.
31	ZHANG B, ZHANG Y, LI R, et al. The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis[J]. J Orthop Surg Res, 2020, 15(1): 51.
32	HAN Y, GUO W, REN T, et al. Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis[J]. Cancer Lett, 2019, 440/441: 116-125.
33	SU Y, ZHOU Y, SUN Y J, et al. Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1[J]. J Mol Med (Berl), 2019, 97(1): 49-61.
34	CHENG Z, WANG L, WU C, et al. Tumor-derived exosomes induced M2 macrophage polarization and promoted the metastasis of osteosarcoma cells through tim-3[J]. Arch Med Res, 2021, 52(2): 200-210.
35	QUERO L, TIADEN A N, HANSER E, et al. miR-221-3p drives the shift of M2-macrophages to a pro-inflammatory function by suppressing JAK3/STAT3 activation [J]. Front Immunol, 2019, 10: 3087.
36	CHEN Y, TANG G, QIAN H, et al. LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization[J]. Aging (Albany NY), 2021, 13(10): 14258-14276.
37	CAO H, QUAN S, ZHANG L, et al. BMPR2 expression level is correlated with low immune infiltration and predicts metastasis and poor survival in osteosarcoma[J]. Oncol Lett, 2021, 21(5): 391.
38	SONG Y J, XU Y, ZHU X, et al. Immune landscape of the tumor microenvironment identifies prognostic gene signature CD4/CD68/CSF1R in osteosarcoma[J]. Front Oncol, 2020, 10: 1198.
39	LIANG X, GUO W, REN T, et al. Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta[J]. Cancer Lett, 2020, 480: 4-14.
40	LUO Z W, LIU P P, WANG Z X, et al. Macrophages in osteosarcoma immune microenvironment: implications for immunotherapy[J]. Front Oncol, 2020, 10: 586580.
41	ZHENG P, CHEN L, YUAN X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells[J]. J Exp Clin Cancer Res, 2017, 36(1): 53.
42	DONG X, SUN R, WANG J, et al. Glutathione S-transferases P1-mediated interleukin-6 in tumor-associated macrophages augments drug-resistance in MCF-7 breast cancer[J]. Biochem Pharmacol, 2020, 182: 114289.
43	NAJAFI M, FARHOOD B, MORTEZAEE K. Cancer stem cells (CSCs) in cancer progression and therapy[J]. J Cell Physiol, 2019, 234(6): 8381-8395.
44	YANG L, DONG Y, LI Y, et al. IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-κB/Notch1 pathway in non-small cell lung cancer[J]. Int J Cancer, 2019, 145(4): 1099-1110.
45	SHAO X J, XIANG S F, CHEN Y Q, et al. Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells[J]. Acta Pharmacol Sin, 2019, 40(10): 1343-1350.
46	吴婧婧, 孙妩弋, 魏伟. 肿瘤相关巨噬细胞在肝癌中的作用及靶向治疗研究进展 [J]. 安徽医科大学学报, 2017, 52(12): 1901-1905.
	WU J J, SUN W Y, WEI W. Research progress on the role of tumor-associated macrophages in liver cancer and targeted therapy [J]. Journal of Anhui Medical University, 2017, 52(12): 1901-1905.
47	宋呈祥. CTRP9对小鼠巨噬细胞胞葬作用的影响及机制研究 [D]. 济南:山东大学, 2021.
	SONG C X. The effect of CTRP9 on the efferocytosis of mouse macrophages and its mechanism [D]. Jinan: Shandong University, 2021.
48	MYERS K V, AMEND S R, PIENTA K J. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment[J]. Mol Cancer, 2019, 18(1): 94.
49	DORAN A C, YURDAGUL A, TABAS I. Efferocytosis in health and disease[J]. Nat Rev Immunol, 2020, 20(4): 254-267.
50	高松, 徐培钧, 郝继辉. 巨噬细胞在肿瘤发展及治疗中的研究进展 [J]. 中国细胞生物学学报, 2022, 44(4): 572-582.
	GAO S, XU P J, HAO J H. Research progress of macrophages in tumor development and treatment [J]. Chinese Journal of Cell Biology, 2022, 44(4): 572-582.
51	ZHAO S J, JIANG Y Q, XU N W, et al. SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex[J]. Oncogene, 2018, 37(8): 1049-1061.
52	RIBEIRO N, SOUSA S R, BREKKEN R A, et al. Role of SPARC in bone remodeling and cancer-related bone metastasis [J]. J Cell Biochem, 2014, 115(1): 17-26.
53	SÉGALINY A I, MOHAMADI A, DIZIER B, et al. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment[J]. Int J Cancer, 2015, 137(1): 73-85.
54	CHEN D, XIE J, FISKESUND R, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype[J]. Nat Commun, 2018, 9(1): 873.
55	XIAO Q, ZHANG X, WU Y, et al. Inhibition of macrophage polarization prohibits growth of human osteosarcoma [J]. Tumour Biol, 2014, 35(8): 7611-7616.
56	PUNZO F, BELLINI G, TORTORA C, et al. Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells [J]. Oncotarget, 2020, 11(7): 687-698.
57	尹芳芳, 许磊晶, 贺美娟, 等. 甲氨蝶呤诱导巨噬细胞M1极化促进骨肉瘤细胞凋亡的实验研究 [J]. 现代生物医学进展, 2020, 20(11): 2006-2011.
	YIN F F, XU L J, HE M J, et al. Methotrexate induces M1 polarization of macrophages and promotes apoptosis of osteosarcoma cells [J]. Advances in Modern Biomedicine, 2020, 20(11): 2006-2011.
58	GOWD V, AHMAD A, TARIQUE M, et al. Advancement of cancer immunotherapy using nanoparticles-based nanomedicine[J]. Semin Cancer Biol, 2022, 86(pt 2): 624-644.
59	ZHANG Y, YUAN T, LI Z, et al. Hyaluronate-based self-stabilized nanoparticles for immunosuppression reversion and immunochemotherapy in osteosarcoma treatment[J]. ACS Biomater Sci Eng, 2021, 7(4): 1515-1525.
60	MOHANTY S, YERNENI K, THERUVATH J L, et al. Nanoparticle enhanced MRI can monitor macrophage response to CD47 MAb immunotherapy in osteosarcoma[J]. Cell Death Dis, 2019, 10(2): 36.
61	XU J F, PAN X H, ZHANG S J, et al. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models[J]. Oncotarget, 2015, 6(27): 23662-23670.
62	MOHANTY S, AGHIGHI M, YERNENI K, et al. Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell ‘don′t eat me’ signals off and ‘eat me’ signals on[J]. Mol Oncol, 2019, 13(10): 2049-2061.
63	王成吕, 聂玉洁, 潘润桑, 等. 三种新兴的免疫检查点分子在肿瘤免疫治疗中的研究进展 [J]. 现代肿瘤医学, 2022, 30(7): 1308-1312.
	WANG C L, NIE Y J, PAN R S, et al. Research progress of three emerging immune checkpoint molecules in tumor immunotherapy [J]. Modern Oncology Medicine, 2022, 30(7): 1308-1312.
64	曾峥, 罗丹玲, 钟明利, 等. 免疫检查点抑制剂抗肿瘤作用的影响因素研究进展 [J]. 中南药学, 2022, 20(8): 1867-1874.
	ZENG Z, LUO D L, ZHONG M L, et al. Research progress on influencing factors of anti-tumor effect of immune checkpoint inhibitors [J]. Zhongnan Pharmacy, 2022, 20(8): 1867-1874.
65	ZHENG B, REN T, HUANG Y, et al. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse[J]. J Hematol Oncol, 2018, 11(1): 16.
66	LIGON J A, CHOI W, COJOCARU G, et al. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes[J]. J Immunother Cancer, 2021, 9(5): e001772
67	TOPALIAN S L, HODI F S, BRAHMER J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer [J]. N Engl J Med, 2012, 366(26): 2443-2454.

[1]	梅艳青, 韩雨洁, 翁文筠, 张蕾, 唐玉杰. 靶向抑制CDK12/13在高级别胶质瘤中的体外治疗效果和作用分子机制探究[J]. 上海交通大学学报（医学版）, 2023, 43(5): 545-559.
[2]	徐瀛濂, 田静, 张翔, 赵顺英. 气道上皮细胞在哮喘发病机制中的作用研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(5): 619-623.
[3]	刘铁鑫, 林俊卿, 郑宪友. 靶向亚细胞结构治疗脊髓损伤的研究进展[J]. 上海交通大学学报（医学版）, 2023, 43(2): 230-236.
[4]	马芳芳, 秦洁洁, 任灵杰, 唐笑梅, 刘佳, 施敏敏, 蒋玲曦. 基于水凝胶微球建立胰腺癌原代细胞的3D培养模型[J]. 上海交通大学学报（医学版）, 2023, 43(1): 79-87.
[5]	韩永琪, 韩达, 閤谦, 姬丁坤, 谭蔚泓. 核酸适体药物偶联物——肿瘤精准治疗新风向[J]. 上海交通大学学报（医学版）, 2022, 42(9): 1176-1181.
[6]	林家俞, 秦洁洁, 蒋玲曦. 肿瘤微环境中免疫细胞的代谢研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(8): 1122-1130.
[7]	王雨心, 孙瑞琪, 刘坚华, 何伟娜. 开发用于肿瘤微环境成像的pH敏感荧光探针[J]. 上海交通大学学报（医学版）, 2022, 42(7): 875-884.
[8]	戚炀炀, 熊鹰. Galectin-9阳性肿瘤相关巨噬细胞在肌层浸润性膀胱癌中的表型、功能及临床治疗意义[J]. 上海交通大学学报（医学版）, 2022, 42(12): 1666-1676.
[9]	李若楠, 陈小科, 许元元, 谭强. ⅠB~ⅢA期非小细胞肺癌患者术后辅助靶向治疗研究进展[J]. 上海交通大学学报（医学版）, 2022, 42(11): 1612-1619.
[10]	李静威, 王俐文, 蒋玲曦, 詹茜, 陈皓, 沈柏用. 胰腺癌免疫抑制性肿瘤微环境研究综述[J]. 上海交通大学学报(医学版), 2021, 41(8): 1103-1108.
[11]	那迪娜·帕尔哈提null, 严妍, 车千纪, 罗菁, 刘鑫男, 李斌. 嵌合抗原受体T细胞疗法在胶质母细胞瘤中的应用与展望[J]. 上海交通大学学报(医学版), 2021, 41(7): 982-986.
[12]	张佳玲, 张凤春, 徐迎春. 乳腺癌脑转移系统治疗的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(5): 671-677.
[13]	顾琦晟, 张米粒, 曹灿, 李继坤. 基于TCGA数据库分析胃癌可变剪接与肿瘤免疫的关系[J]. 上海交通大学学报(医学版), 2021, 41(4): 448-458.
[14]	刘梦珂, 纪濛濛, 程林, 黄金艳, 孙晓建, 赵维莅, 王黎. 黄芩苷抗肿瘤作用机制的研究进展[J]. 上海交通大学学报(医学版), 2021, 41(2): 246-250.
[15]	赵伟光，刘志宏. 肿瘤相关成纤维细胞调控肿瘤免疫炎症微环境的研究进展[J]. 上海交通大学学报(医学版), 2020, 40(9): 1288-1293.

骨肉瘤免疫微环境中肿瘤相关巨噬细胞及其靶向治疗的研究进展

Research progress of tumor-associated macrophages in immune microenvironment and targeted therapy of osteosarcoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 67

相关文章 15

编辑推荐

Metrics